AlphaCrest Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-5,061
| Closed | -$1.01M | – | 56 |
|
|
2022
Q3 | $1.01M | Sell |
5,061
-483
| -9% | -$96.7K | 0.06% | 603 |
|
|
2022
Q2 | $809K | Buy |
5,544
+1,781
| +47% | +$260K | 0.04% | 756 |
|
|
2022
Q1 | $614K | Buy |
3,763
+974
| +35% | +$159K | 0.03% | 793 |
|
|
2021
Q4 | $473K | Sell |
2,789
-2,119
| -43% | -$359K | 0.02% | 1117 |
|
|
2021
Q3 | $927K | Buy |
4,908
+2,271
| +86% | +$429K | 0.05% | 649 |
|
|
2021
Q2 | $447K | Sell |
2,637
-294
| -10% | -$49.8K | 0.02% | 988 |
|
|
2021
Q1 | $414K | Sell |
2,931
-5,467
| -65% | -$772K | 0.02% | 888 |
|
|
2020
Q4 | $1.09M | Buy |
+8,398
| New | +$1.09M | 0.09% | 292 |
|
|
2020
Q3 | – | Sell |
-1,421
| Closed | -$210K | – | 1078 |
|
|
2020
Q2 | $210K | Sell |
1,421
-1,789
| -56% | -$264K | 0.03% | 823 |
|
|
2020
Q1 | $349K | Sell |
3,210
-4,598
| -59% | -$500K | 0.04% | 728 |
|
|
2019
Q4 | $899K | Sell |
7,808
-18,600
| -70% | -$2.14M | 0.07% | 414 |
|
|
2019
Q3 | $2.12M | Buy |
+26,408
| New | +$2.12M | 0.13% | 212 |
|